(Q38377528)

7 November 2017

Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 Blockade (English)

1 reference

7 November 2017

2

1 reference

PubMed publication ID

2 September 2017

18

1 reference

PubMed publication ID

2 September 2017

17

Justin M Balko

1 reference

7 November 2017

5

Yaomin Xu

1 reference

7 November 2017

27

Christine M Lovly

1 reference

7 November 2017

Douglas B Johnson

1

1 reference

7 November 2017

Matthew J Rioth

3

1 reference

7 November 2017

Erik Yusko

4

1 reference

7 November 2017

Xingyi Guo

6

1 reference

7 November 2017

Riley C Ennis

7

1 reference

7 November 2017

David Fabrizio

8

1 reference

7 November 2017

Zachary R Chalmers

9

1 reference

7 November 2017

Joel Greenbowe

10

1 reference

7 November 2017

Siraj M Ali

11

1 reference

7 November 2017

Sohail Balasubramanian

12

1 reference

7 November 2017

James X Sun

13

1 reference

7 November 2017

Yuting He

14

1 reference

7 November 2017

Dennie T Frederick

15

1 reference

7 November 2017

Igor Puzanov

16

1 reference

7 November 2017

Jeffrey S Ross

19

1 reference

7 November 2017

Catherine Sanders

20

1 reference

7 November 2017

Harlan Robins

21

1 reference

7 November 2017

Yu Shyr

22

1 reference

7 November 2017

Vincent A Miller

23

1 reference

7 November 2017

Philip J Stephens

24

1 reference

7 November 2017

Ryan J Sullivan

25

1 reference

7 November 2017

Jeffrey A Sosman

26

1 reference

7 November 2017

26 September 2016

1 reference

Cancer Immunology Research

7 November 2017

1 reference

7 November 2017

4

1 reference

7 November 2017

11

1 reference

7 November 2017

959-967

1 reference

Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma

7 November 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5134329

MYC regulates the antitumor immune response through CD47 and PD-L1

23 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5134329

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial

23 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5134329

Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade

23 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5134329

Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy.

23 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5134329

CANCER. The odds of immunotherapy success

23 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5134329

Genomic correlates of response to CTLA-4 blockade in metastatic melanoma

23 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5134329

Genomic Classification of Cutaneous Melanoma

23 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5134329

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

23 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5134329

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

23 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5134329

Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity

23 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5134329

Pembrolizumab versus Ipilimumab in Advanced Melanoma

23 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5134329

Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer

23 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5134329

Impact of NRAS mutations for patients with advanced melanoma treated with immune therapies

23 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5134329

PD-1 blockade induces responses by inhibiting adaptive immune resistance

23 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5134329

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

23 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5134329

Genetic basis for clinical response to CTLA-4 blockade in melanoma

23 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5134329

Ultra-deep T cell receptor sequencing reveals the complexity and intratumour heterogeneity of T cell clones in renal cell carcinomas

23 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5134329

Clinical activity of ipilimumab for metastatic uveal melanoma: a retrospective review of the Dana-Farber Cancer Institute, Massachusetts General Hospital, Memorial Sloan-Kettering Cancer Center, and University Hospital of Lausanne experience

23 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5134329

Ipilimumab for patients with advanced mucosal melanoma

23 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5134329

Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma

23 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5134329

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

23 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5134329

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

23 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5134329

Common fragile sites, extremely large genes, neural development and cancer

23 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5134329

Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing

23 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5134329

31 August 2018

1 reference

https://pubmed.ncbi.nlm.nih.gov/27671167

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

PD-L1 Testing in Cancer: Challenges in Companion Diagnostic Development

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/27671167

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1158/2326-6066.CIR-16-0143

1 reference

7 November 2017

1 reference

7 November 2017

PubMed publication ID

27671167

1 reference